Patterson Companies upgraded by Piper Sandler with a new price target
$PDCO
Medical Specialities
Health Care
Piper Sandler upgraded Patterson Companies from Neutral to Overweight and set a new price target of $44.00 from $34.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2024 | $23.00 | Neutral | Mizuho |
| 2/29/2024 | $34.00 → $28.00 | Overweight → Neutral | Piper Sandler |
| 2/26/2024 | $36.00 | Outperform | Leerink Partners |
| 5/13/2022 | $36.00 | Outperform | Credit Suisse |
| 3/3/2022 | $30.00 → $32.00 | Equal-Weight | Morgan Stanley |
| 1/31/2022 | $30.00 | Equal-Weight | Morgan Stanley |
| 10/1/2021 | $38.00 | Outperform | Credit Suisse |
Mizuho initiated coverage of Patterson Companies with a rating of Neutral and set a new price target of $23.00
Piper Sandler downgraded Patterson Companies from Overweight to Neutral and set a new price target of $28.00 from $34.00 previously
Leerink Partners initiated coverage of Patterson Companies with a rating of Outperform and set a new price target of $36.00